1. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus
- Author
-
Amanat, Fatima, Strohmeier, Shirin, Meade, Philip, Dambrauskas, Nicholas, M��hlemann, Barbara, Smith, Derek, Vigdorovich, Vladimir, Sather, D Noah, Coughlan, Lynda, Krammer, Florian, Amanat, Fatima [0000-0002-8029-8227], Mühlemann, Barbara [0000-0002-5314-8530], Smith, Derek [0000-0002-2393-1890], Coughlan, Lynda [0000-0001-9880-6560], Krammer, Florian [0000-0003-4121-776X], and Apollo - University of Cambridge Repository
- Subjects
RNA viruses ,Serum Proteins ,Coronaviruses ,Physiology ,viruses ,Antibodies, Viral ,Biochemistry ,Mice ,Medical Conditions ,Immune Physiology ,Chlorocebus aethiops ,Biology (General) ,Enzyme-Linked Immunoassays ,Pathology and laboratory medicine ,Vaccines ,Mice, Inbred BALB C ,Immune System Proteins ,General Neuroscience ,Animal Models ,Medical microbiology ,Antigenic Variation ,Recombinant Proteins ,Infectious Diseases ,Experimental Organism Systems ,Viruses ,Female ,SARS CoV 2 ,Pathogens ,General Agricultural and Biological Sciences ,Research Article ,COVID-19 Vaccines ,SARS coronavirus ,Infectious Disease Control ,QH301-705.5 ,Immunology ,Mouse Models ,Cross Reactions ,Research and Analysis Methods ,Microbiology ,General Biochemistry, Genetics and Molecular Biology ,Antibodies ,Model Organisms ,Virology ,Animals ,Antigens ,Immunoassays ,Vero Cells ,Medicine and health sciences ,General Immunology and Microbiology ,Biology and life sciences ,SARS-CoV-2 ,Organisms ,Viral pathogens ,Proteins ,COVID-19 ,Viral Vaccines ,Antibodies, Neutralizing ,Microbial pathogens ,Animal Studies ,Immunologic Techniques - Abstract
Funder: jpb foundation; funder-id: http://dx.doi.org/10.13039/100007457, Funder: open philanthropy project, Vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been highly efficient in protecting against Coronavirus Disease 2019 (COVID-19). However, the emergence of viral variants that are more transmissible and, in some cases, escape from neutralizing antibody responses has raised concerns. Here, we evaluated recombinant protein spike antigens derived from wild-type SARS-CoV-2 and from variants B.1.1.7, B.1.351, and P.1 for their immunogenicity and protective effect in vivo against challenge with wild-type SARS-CoV-2 in the mouse model. All proteins induced high neutralizing antibodies against the respective viruses but also induced high cross-neutralizing antibody responses. The decline in neutralizing titers between variants was moderate, with B.1.1.7-vaccinated animals having a maximum fold reduction of 4.8 against B.1.351 virus. P.1 induced the most cross-reactive antibody responses but was also the least immunogenic in terms of homologous neutralization titers. However, all antigens protected from challenge with wild-type SARS-CoV-2 in a mouse model.
- Published
- 2022
- Full Text
- View/download PDF